Compare British American Tobacco PLC (BTI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Mesoblast Limited — how do they compare? British American Tobacco PLC trades at $56.94 (market cap $122.36B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: British American Tobacco PLC is far larger — about 55.4× Mesoblast Limited's market cap, and British American Tobacco PLC pays a 5.88% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| BTI | MESO | |
|---|---|---|
Market Cap | $122.36B | $2.21B |
Sector | Consumer Staples | Technology |
52-Week High | $66.70 | $20.96 |
52-Week Low | $50.39 | $12.88 |
Enterprise Value | $166.31B | $2.21B |
Dividend Yield | 5.88% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
